Kartos Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kartos Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 3 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Kartos Therapeutics: 8 sponsored US clinical trials, 3 recruiting.

Kartos Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignancy, with 1 trials.

Upper-quartile sponsor footprint

Kartos Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
RECRUITING Phase 2

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831
RECRUITING Phase 1

KRT-232 and TKI Study in Chronic Myeloid Leukemia

NCT04835584
TERMINATED Phase 2

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT05027867
TERMINATED Phase 1

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT04113616
COMPLETED Phase 1

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

NCT02110355
COMPLETED Phase 1

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

NCT02016729
COMPLETED Phase 1

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2
Phase 3 1

Therapeutic Areas

Advanced Malignancy 1
Oncology Patients 1
MF 1
Post-ET Myelofibrosis 1
Post-PV MF 1
Chronic Myeloid Leukemia 1
Myelofibrosis 1
Oncology 1
Primary Myelofibrosis 1
Acute Myeloid Leukemia 1

What is open in the Kartos Therapeutics pipeline

3 recruiting of 8 indexed (38% open); 3 completed (38%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Advanced Malignancy (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kartos Therapeutics: open-pipeline peers nationwide

Peers matched on 8 registered trials and 38% open enrollment, not the therapeutic-area sidebar.

Kartos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8.088.1 0%10%20%30%40% Total trials Recruiting share Kartos TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)American Thrombosis and Hemostasis NetworkAskBioAthletic Greens InternationalBanner Health
Kartos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kartos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 38% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kartos Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Kartos Therapeutics or any single study.

  • 3 of Kartos Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Malignancy is the condition Kartos Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignancy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kartos Therapeutics pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.